Due to continued uncertainty around how aggressively to treat early multiple sclerosis (MS), a group of researchers recently analyzed long-term outcomes in a population-based cohort according to initial treatment strategy.
Due to continued uncertainty around how aggressively to treat early multiple sclerosis (MS), a group of researchers recently analyzed long-term outcomes in a population-based cohort according to initial treatment strategy.
The results, published in JAMA Neurology, found that in a real-world setting, long-term outcomes were more favorable following early intensive therapy when compared with first-line moderate-efficacy disease-modifying therapy (DMT).
Data were collected from January 1998 to December 2016. An analysis was performed shortly thereafter in January 2017. A total of 720 patients were prescribed a DMT, of which 592 were then included in the study. Patients were then further classified according to first-line treatment strategy: high-efficacy, early intensive treatment (EIT); or moderate-efficacy DMT, escalation (ESC).
In total, 104 patients (17.6%) had been prescribed an EIT, while 488 patients (82.4%) began treatment with a DMT. Of the 488 patients originally prescribed a DMT, 58 (11.9%) subsequently escalated treatment to an EIT. This intensification of treatment was caused largely by relapses. The median time to sustained accumulation of disability (SAD) was 6.0 (95% CI, 3.17-9.16) years for those in the EIT arm, and 3.14 (95% CI, 2.77-4.00) years for patients in the ESC arm (P = .05).
For the patients within the ESC group who escalated to EIT as a second-line treatment, the median time to SAD was 3.3 years (95% CI, 1.8-5.6), compared with the EIT group log-rank test (P = .08). After the investigators adjusted for relevant covariates, there was no identified difference between the groups in risk of SAD; however, of the patients who escalated to EIT, 60% were observed to develop SAD while still receiving initial moderate-efficacy treatment prior to escalation.
Overall, investigators found that long-term outcomes were favorable following early intensive therapy versus first-line moderate-efficacy DMT. Importantly, the study authors noted that “contemporary surveillance strategies and escalation protocols may be insufficiently responsive. This finding is particularly relevant as patients in real-world practice are typically selected for an EIT approach to therapy on the basis of clinical and radiological features predictive of a poor outcome.”
Based on these findings, the authors believe that there is a need to conduct a prospective randomized clinical trial in the future.
Reference
Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis [published online February 18, 2019]. JAMA Neurol. doi:10.1001/jamaneurol.2018.4905
Distinguishing Biomarkers Identified in MS Outcomes
March 19th 2024Results from this cohort study found that levels of glial fibrillary acid protein, cerebral spinal fluid, and neurofilament heavy chain are distinguishable biomarkers that are associated with disease outcomes in multiple sclerosis (MS).
Read More
Choroid Plexus Indicated in MS Pathology
February 9th 2024A longitudinal, observational study found that the choroid plexus, a network of blood vessels in each ventricle of the brain, plays a potential role in the neurodegenerative and chronic inflammatory process experienced by patients with relapsing remitting multiple sclerosis (MS).
Read More